1. Folic acid conjugated bovine serum albumin: An efficient smart and tumor targeted biomacromolecule for inhibition folate receptor positive cancer cells.
- Author
-
Nosrati H, Abbasi R, Charmi J, Rakhshbahar A, Aliakbarzadeh F, Danafar H, and Davaran S
- Subjects
- Animals, Calorimetry, Differential Scanning, Cattle, Cell Line, Tumor, Drug Carriers chemistry, Drug Delivery Systems, Drug Liberation, Hemolysis, Humans, Microscopy, Atomic Force, Nanoparticles chemistry, Nanoparticles ultrastructure, Particle Size, Spectroscopy, Fourier Transform Infrared, Antineoplastic Agents chemistry, Antineoplastic Agents pharmacology, Folic Acid chemistry, Macromolecular Substances chemistry, Macromolecular Substances pharmacology, Serum Albumin, Bovine chemistry
- Abstract
This work described a folic acid conjugated delivery of chrysin-loaded bovine serum albumin nanoparticles, which could overcome the nonspecific targeting disadvantage. Chrysin (5, 7-dihydroxyflavone) is a natural flavonoid which have some significant biological effects on the processes of chemical defense. Chrysin loaded bovine serum albumin nanoparticles (Chrysin-BSA NPs) were synthesized by a simple desolvation procedure. Afterward, folic acid (FA) was conjugated to the surface of Chrysin-BSA NPs by carbodiimide chemistry (Chrysin-BSA-FA NPs). The resultant Chrysin-BSA-FA NPs showed a spherical shape, with a hydrodynamic diameter of 97.5 ± 5.8 nm (mean ± SD) nm and a ζ-potential of -11.3 mV. The in vitro drug release study of chrysin presented a sustained and controlled release pattern. Hemolysis assay and cytotoxicity study results on HFF-2 cell line show that as prepared BSA NPs are biocompatible. Both the Chrysin-BSA NPs and Chrysin-BSA-FA NPs prompted an enhanced cancer cell cytotoxic effect in contrast to chrysin solution. These data recommended that the folate-modified chrysin -loaded vehicle, which demonstrated better biocompatibility and potential superiority, could be a suitable cancer therapy in targeting tumors in the future., (Copyright © 2018 Elsevier B.V. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF